Inactive Instrument

Otonomy

Equities

OTIC

US68906L1052

Otonomy, Inc. Announces Executive Changes

December 19, 2022 at 05:27 pm EST

On December 15, 2022, Otonomy, Inc. announced in connection with the Reduction, Paul E. Cayer, Chief Financial Officer, terminated employment with the Company. Mr. Cayer continues to serve as Chief Financial and Business Officer and Secretary, was appointed President effective December 15, 2022.

Latest news about Otonomy

Otonomy, Inc. Announces Executive Changes	23-03-28	CI
Otonomy, Inc. Announces Chief Financial Officer Changes	23-03-28	CI
Otonomy, Inc. Announces Executive Changes	23-02-16	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from S&P TMI Index	22-12-28	CI
Otonomy Shares to be Suspended From Nasdaq Trading	22-12-22	MT
Otonomy, Inc.(OTCPK:OTIC) dropped from NASDAQ Composite Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Growth Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Growth Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Value Index	22-12-22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Value Index	22-12-22	CI
Otonomy Plans to File for Liquidation; Lays off All Employees; Shares Fall	22-12-20	MT
Otonomy, Inc. Plans Reduce Its Workforce	22-12-19	CI
Otonomy, Inc. Announces Executive Changes	22-12-19	CI
Otonomy, Inc. Announces Executive Changes	22-12-19	CI
Otonomy, Inc. Announces Termination of David A. Weber as Chief Executive Officer	22-12-19	CI
Otonomy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
North American Morning Briefing : Midterm Outcome -2-	22-11-09	DJ
North American Morning Briefing : All Eyes on Bank -2-	22-10-14	DJ
Top Midday Decliners	22-10-13	MT
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive	22-10-13	MT
Piper Sandler Downgrades Otonomy to Neutral From Overweight, Lowers Price Target to $0.50 From $3	22-10-13	MT
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss	22-10-13	MT
Otonomy, Inc Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss	22-10-13	CI

Chart Otonomy

Duration

Period

More charts

Company Profile

Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Sector

More about the company